Mastodawn

𝗔𝘀 𝗶𝗻𝘁𝗲𝗿𝗻𝗮𝘁𝗶𝗼𝗻𝗮𝗹 𝘁𝗿𝗮𝘃𝗲𝗹 𝗿𝗲𝗯𝗼𝘂𝗻𝗱𝘀, 𝘁𝗿𝗮𝘃𝗲𝗹 𝗵𝗲𝗮𝗹𝘁𝗵 𝗶𝘀 𝗯𝗲𝗰𝗼𝗺𝗶𝗻𝗴 𝗮 𝗯𝗶𝗴𝗴𝗲𝗿 𝗽𝗿𝗶𝗼𝗿𝗶𝘁𝘆 𝗳𝗼𝗿 𝗰𝗼𝗻𝘀𝘂𝗺𝗲𝗿𝘀, 𝗰𝗹𝗶𝗻𝗶𝗰𝘀, 𝗮𝗻𝗱 𝗽𝗵𝗮𝗿𝗺𝗮𝗰𝗶𝗲𝘀.
The 𝗚𝗹𝗼𝗯𝗮𝗹 𝗧𝗿𝗮𝘃𝗲𝗹𝗲𝗿𝘀 𝗗𝗶𝗮𝗿𝗿𝗵𝗲𝗮 𝗧𝗿𝗲𝗮𝘁𝗺𝗲𝗻𝘁 𝗠𝗮𝗿𝗸𝗲𝘁 𝗶𝘀 𝘃𝗮𝗹𝘂𝗲𝗱 𝗮𝘁 𝗨𝗦𝗗 𝟭.𝟯 𝗯𝗶𝗹𝗹𝗶𝗼𝗻, supported by rising travel volumes, higher awareness of travel-related health risks, OTC access, prescription treatments, probiotics, and preventive health planning before trips.
𝗥𝗲𝗮𝗱 𝗺𝗼𝗿𝗲: https://www.kenresearch.com/global-travelers-diarrhea-treatment-market?utm_source=Mastodon&utm_medium=Social&utm_campaign=Aniket
#TravelHealth #HealthcareMarket #Pharmaceuticals #KenResearch

Global Travelers Diarrhea Market | 2019 – 2030 | Ken Research

Global Travelers Diarrhea Treatment Market is valued at USD 1.3 billion, driven by rising international travel and health awareness. Key segments include antibiotics and individual travelers.

CBC Windsor 1d ago

Windsor pharmaceutical company expanding to make prescription drugs for cystic fibrosis patients
Development is underway at a Windsor pharmaceutical facility to make prescription drugs that will primarily help cystic fibrosis patients.
https://www.cbc.ca/news/canada/windsor/cystic-fibrosis-drug-windsor-9.7232126?cmp=rss

Victator Jun 4

#bigpharma #pharmaceuticals

Victator Jun 4

#BigPharm #bigpharma #pharmaceuticals #NoBillionaires #AmericanCapitalismCrisis

Research solutions Jun 2

The Global Acetonitrile Market is expected to grow from USD 889.48 Million in 2026 to USD 1,160.57 Million by 2035, with a CAGR of 3%.

Growth is supported by demand from pharmaceutical manufacturing, laboratory testing, HPLC applications, and chemical processing.

Sample Report:
https://www.researchreportsworld.com/enquiry/request-sample/501360

#Acetonitrile #ChemicalIndustry #Pharmaceuticals #MarketResearch

The Times Of Central Asia | Eurasian Publication & News Online [Unofficial]Jun 1

Investment in Kazakhstan’s Pharmaceutical Manufacturing More Than Triples in Three Years

https://fed.brid.gy/r/https://timesca.com/investment-in-kazakhstans-pharmaceutical-manufacturing-more-than-triples-in-three-years/

The Japan Times May 29

In a bid to curb insurance premium hikes for the working population, Japan has passed legislation to raise co-payments for prescription medications with ingredients and effects similar to over-the-counter drugs. https://www.japantimes.co.jp/news/2026/05/29/japan/science-health/medical-bill-passes-parliament/?utm_medium=Social&utm_source=mastodon #japan #sciencehealth #insurance #medicine #pharmaceuticals #pregnancy #diet #health

Japan passes bill to raise co-payments for prescription drugs similar to OTC counterparts

The health ministry plans to require individuals to bear additional costs for some 1,100 over-the-counter-like prescription drugs starting in March 2027.

The Japan Times

Global News Health May 28

Novo Nordisk will slash Ozempic price for some, ‘aligning’ with generics
Ozempic and Wegovy, both produced by Novo Nordisk, currently cost hundreds of dollars a month, depending on the dosage dispensed, in some cases more than $450.
#Health #GLP1 #Ozempic
https://globalnews.ca/news/11863331/novo-nordisk-slash-ozempic-price-generics/

Headlines Africa May 28

Africa: Building Ethiopia's Pharmaceutical Future - From Strong Regulation to Local Production: [World Bank] Ethiopia is transforming from an import-dependent market into a pharmaceutical manufacturing hub. After becoming the 9th African nation to reach WHO Maturity Level 3, local production now exceeds 40% of medicine supply. This WBG feature examines how regulation, the Kilinto Special Economic Zone,… http://newsfeed.facilit8.network/TSlhSm #Ethiopia #Pharmaceuticals #HealthSovereignty #LocalProduction #WHO